IPGaia Inc. (President & CEO, Yasunori Yamaguchi, “IPG”) and Kyoto University (Provost, Nagahiro Minato) have entered into a Master Collaborative Research and Development Agreement (“this agreement”) dated November 17, 2023. This agreement establishes a formal framework for the incorporation of promising drug target leads from Kyoto University into IPG’s drug discovery platform. This agreement enables Kyoto University to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG is soliciting drug target leads from a wide range of research institutions, including global academia and pharmaceutical companies, and is steadily expanding to the seventh institution, Kyoto …
Duke-NUS and Japan-based IPGaia announce partnership to accelerate innovation in drug discovery
SINGAPORE, 7 November 2023 – Duke-NUS Medical School (Duke-NUS) and IPGaia, Inc. (IPG) have signed an agreement to jointly advance drug discovery and development from academia to industry, to bring the benefits of translational research to patients. Through this partnership, Duke-NUS will propose drug targets to IPG, which will, in turn, identify and develop lead compounds with the goal of licensing clinic-ready candidates to pharmaceutical companies. The collaboration brings together IPG’s expertise in commercial research and development and its industry network with Duke-NUS’ strong capabilities in world-class discovery research in areas of global importance. Aligning with Singapore’s national focus to build a vibrant ecosystem for biomedical innovation, Duke-NUS’ five …
Thirty Companies have Accepted to Join IPG Membership
IPGaia, Inc., (“IPG”) operates IPG membership, which was established with the mission of providing pharmaceutical companies with more efficient access to clinical development drug candidates. We are happy to announce today that the number of member companies accepting IPG membership has exceeded thirty domestic and foreign pharmaceutical companies. Ten out of the thirty member companies are global pharmaceutical companies from abroad, and seven of the fifteen top pharmaceutical companies by revenue in the world (according to our research) have accepted to join the IPG membership. IPG is a platform provider for drug discovery and development in pre-clinical stage, and the company efficiently generates high-quality clinical development candidates from drug discovery …
Continue reading “Thirty Companies have Accepted to Join IPG Membership”